{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:17:32Z","timestamp":1781821052427,"version":"3.54.5"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:p>\n            The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC toward\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            , including \u03b2-lactamase expressing Ambler classes A, B, and D, was 8 to 16 \u03bcg\/ml.\n          <\/jats:p>","DOI":"10.1128\/aac.02416-20","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T13:35:24Z","timestamp":1611149724000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["<i>In Vivo<\/i>\n            Targeting of Escherichia coli with Vancomycin-Arginine"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5094-8121","authenticated-orcid":true,"given":"Lewis F.","family":"Neville","sequence":"first","affiliation":[{"name":"SuperTrans Medical Ltd., Ness Ziona, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itamar","family":"Shalit","sequence":"additional","affiliation":[{"name":"SuperTrans Medical Ltd., Ness Ziona, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Warn","sequence":"additional","affiliation":[{"name":"Magic Bullet Consulting, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-6130","authenticated-orcid":true,"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Chicago College of Pharmacy and Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuzhi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline B.","family":"Chosy","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Wender","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Stanford University, Stanford, California, USA"},{"name":"Department of Chemical and Systems Biology, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-1814","authenticated-orcid":true,"given":"Lynette","family":"Cegelski","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob T.","family":"Rendell","sequence":"additional","affiliation":[{"name":"SuperTrans Medical Ltd., Ness Ziona, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_2_3_2","volume-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"Tacconelli E","year":"2017","unstructured":"Tacconelli E, Magrini N. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.01.020"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00181-19"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.8b08711"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202002727"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202007022"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00258"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00258"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01093"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00922-10"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03502-14"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00565"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.01.008"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.521"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.7.1771-1777.2000"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw228"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00062-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00281-17"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-18"},{"key":"e_1_3_2_23_2","volume-title":"Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","author":"FDA","year":"2005","unstructured":"FDA. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Washington, DC. https:\/\/www.fda.gov\/media\/72309\/download."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00114"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00125-13"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611040-00001"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33826-9"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22308"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13598"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2013"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02416-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02416-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:40:57Z","timestamp":1645486857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02416-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3,18]]}},"alternative-id":["10.1128\/AAC.02416-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.02416-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"2020-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02416-20"}}